Company intelligence / Profile preview
Eliksa Therapeutics
Salt Lake City, Utah, United Stateseliksa.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Venture-backed biotech developing regenerative therapies for rare diseases; lead asset ELK‑003 eye drops now recruiting for Phase I trial targeting ocular EB.
- Therapeutic areas
- CardiovascularOphthalmologyRare Diseases
- Modalities
- BiologicalsRegenerative medicine
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Militia Hill VenturesBen Franklin Technology Partners
Beyond the preview
Go deeper on Eliksa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eliksa Therapeutics.